Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hereditary angioedema
Economic burden and healthcare resource utilization
7 evidence topics · 7 sources
Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims
“A total of 328 patients were included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (67%) had ≥1 post-index on-demand therapy claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs with lanadelumab compared with berotralstat: US claims
“Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment costs over time with lanadelumab: US claims
“Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect costs of on-demand treatment alone: US patient survey
“Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual per-patient costs by attack severity before current prophylactic agents: US patient survey
“Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hospital costs account for 67% of direct medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resource use after insurance delays or denials of prophylaxis
“A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five percent of respondents reported more urgent care or emergency department visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote